Related Experiment Video
Updated: Jul 11, 2026
07:46
Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
Published on: June 5, 2012
In vitro activity of ABT-773 against anaerobic bacteria
E Sillerström1, E Wahlund, C E Nord
1Department of Microbiology, Pathology and Immunology, Huddinge University Hospital, Stockholm, Sweden.
Summary
The novel antimicrobial ABT-773 shows potent in vitro activity against anaerobic bacteria. It was found to be as effective as imipenem, demonstrating significant potential for treating anaerobic bacterial infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Anaerobic bacteria are significant pathogens responsible for various infections.
- The emergence of antimicrobial resistance necessitates the development of new therapeutic agents.
- Understanding the in vitro efficacy of novel compounds is crucial for guiding clinical treatment strategies.
Purpose of the Study:
- To evaluate the in vitro antimicrobial activity of ABT-773 against a diverse panel of anaerobic bacteria.
- To compare the efficacy of ABT-773 with established antimicrobial agents.
Main Methods:
- Agar dilution method was employed to assess antimicrobial activity.
- 354 clinical isolates of anaerobic bacteria were tested.
- Comparative analysis included azithromycin, clarithromycin, roxithromycin, erythromycin, cefoxitin, imipenem, clindamycin, and metronidazole.
Main Results:
- ABT-773 demonstrated significant in vitro activity against anaerobic bacteria.
- The compound's efficacy was comparable to that of imipenem.
- Both ABT-773 and imipenem exhibited the highest antimicrobial activity among the agents tested.
Conclusions:
- ABT-773 is a promising antimicrobial agent with potent activity against anaerobic bacteria.
- Its efficacy suggests potential as a therapeutic option for anaerobic infections.
- Further clinical investigation is warranted to confirm its therapeutic value.
